Home

Impactful communications for life science companies

Insight_panel

Insight

We have a wealth of insights to draw from to point you in the right direction and provide a 360 degree approach to your communications strategy.

Strategy_panel

Strategy

We’re creative problem solvers and we’ll help you develop a tailored communications plan and advise on best tactics to make the strategy come to life and have impact.

Impact_panel

Impact

When all is said and done, we’ll make sure your communications activities have made a impact to help you along the road to success.

Blogs

Why Milan Punches Above Its Weight For Biotech Partnering

BIO-Europe Blog: Can cell and gene therapy revolutionize the rules of healthcare?

“Scius comes from the Latin word meaning insight, skilled or well informed.”

Case Studies

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

AnaMar AB

Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

AnaMar AB

Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Contact

If you would like to learn more about how we can help you, please contact us: info@sciuscommunications.com